Lyvgen Entered into a Clinical Collaboration with BMS to Evaluate LVGN7409 + Nivolumab for Non-Small Cell Lung Cancer
Shots:
- The companies collaborated to initiate the P-II clinical trial evaluating LVGN7409 + docetaxel or nivolumab in patients with advanced/metastatic NSCLC. The study is expected to be initiated in H1’23
- Lyvgen gets the commercial and development rights globally to LVGN7409 & will be responsible for sponsoring the study and BMS will provide nivolumab for the combination trial
- The study aims to show that when added to the current SoC therapy, CD40 stimulation can improve anti-tumor efficacy and reverse an immune-suppressed tumor microenvironment characterized by drug resistance. LVGN7409 is a next-generation CD40 agonistic mAb that has been developed by the Lyvgen xLinkAb platform
Ref: PRNewswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
